ABSTRACT: Introduction: ALK rearranged Non Small Cell Lung Cancers (NSCLCs) represent a distinct subgroup of patients with peculiar clinic-pathological features. These patients exhibit dramatic responses when treated with the ALK tyrosine kinase inhibitor Crizotinib, albeit Central Nervous System (CNS) activity is much less impressive than that observed against extracranial lesions. CNS involvement has become increasingly observed in these patients, given their prolonged survival. Several novel generation ALK inhibitors have been developing to increase CNS penetration and to provide more complete ALK inhibition. Areas covered: The CNS activity of Crizotinib and novel generation ALK inhibitors will be summarized in this review, evaluating the strengths and weaknesses of the therapeutic strategies developed to date in this specific subgroup of NSCLCs with a look towards the future. Expert commentary: In the next few years, the results of ongoing comparative head-to-head trials will provide the definitive conclusions on the optimal treatment sequence in ALK-rearranged NSCLCs. Moreover, ongoing clinical trials with novel-generation ALK inhibitors will produce more evidences on the best approach in the growing number of ALK-positive NSCLCs with CNS involvement.

Russo, A., Franchina, T., Ricciardi, G., Ferraro, G., Scimone, A., Bronte, G., et al. (2016). Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance. EXPERT REVIEW OF ANTICANCER THERAPY, 16(6), 615-623 [10.1080/14737140.2016.1182427].

Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance

Ferraro, Giuseppa;Bronte, Giuseppe;Russo, Antonio;Rolfo, Christian;
2016

Abstract

ABSTRACT: Introduction: ALK rearranged Non Small Cell Lung Cancers (NSCLCs) represent a distinct subgroup of patients with peculiar clinic-pathological features. These patients exhibit dramatic responses when treated with the ALK tyrosine kinase inhibitor Crizotinib, albeit Central Nervous System (CNS) activity is much less impressive than that observed against extracranial lesions. CNS involvement has become increasingly observed in these patients, given their prolonged survival. Several novel generation ALK inhibitors have been developing to increase CNS penetration and to provide more complete ALK inhibition. Areas covered: The CNS activity of Crizotinib and novel generation ALK inhibitors will be summarized in this review, evaluating the strengths and weaknesses of the therapeutic strategies developed to date in this specific subgroup of NSCLCs with a look towards the future. Expert commentary: In the next few years, the results of ongoing comparative head-to-head trials will provide the definitive conclusions on the optimal treatment sequence in ALK-rearranged NSCLCs. Moreover, ongoing clinical trials with novel-generation ALK inhibitors will produce more evidences on the best approach in the growing number of ALK-positive NSCLCs with CNS involvement.
Settore MED/06 - Oncologia Medica
Russo, A., Franchina, T., Ricciardi, G., Ferraro, G., Scimone, A., Bronte, G., et al. (2016). Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance. EXPERT REVIEW OF ANTICANCER THERAPY, 16(6), 615-623 [10.1080/14737140.2016.1182427].
File in questo prodotto:
File Dimensione Formato  
Central nervous system involvement in ALK-rearranged NSCLC promising strategies to overcome crizotinib resistance..pdf

Solo gestori archvio

Dimensione 903.73 kB
Formato Adobe PDF
903.73 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/249553
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 15
social impact